Compare DexCom, Inc. (DXCM) vs Solaredge Technologies Inc (SEDG) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
DexCom, Inc. vs Solaredge Technologies Inc — how do they compare? DexCom, Inc. trades at $84.11 (market cap $31.86B), while Solaredge Technologies Inc trades at $32.21 (market cap $2.00B). The key difference: DexCom, Inc. is far larger — about 15.9× Solaredge Technologies Inc's market cap, and DexCom, Inc. is trading nearer its 52-week high, Solaredge Technologies Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold DexCom, Inc. for 62 Days and Solaredge Technologies Inc for 34 Days on average.
| DXCM | SEDG | |
|---|---|---|
Market Cap | $31.86B | $2.00B |
Volume | 3,607,070 | 2,739,860 |
Sector | Health | Energy |
52-Week High | $92.34 | $78.51 |
52-Week Low | $54.84 | $28.47 |
Typical Hold Time | 62 Days | 34 Days |
Enterprise Value | $31.32B | $1.86B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
DexCom (DXCM) trades at $84.41, showing modest daily gains of 0.13%. The stock demonstrates strong fundamental performance with consistent earnings beats and robust revenue growth, reaching $4.66 billion in 2025. Technical indicators show a bearish short-term trend with key support at $82. The company maintains impressive profitability with 20.12% net margins and 38.49% ROE, supported by growing adoption of CGM technology in diabetes care.
DXCM presents a compelling growth story with expanding market opportunities in Type 2 diabetes care. Analyst consensus remains strongly bullish with 81% buy ratings and $95.07 price target, suggesting 13% upside. Key risks include reimbursement challenges and competitive pressures. The company's strong cash flow generation and institutional support provide solid foundation for continued growth.
SolarEdge Technologies (SEDG) trades at $32.47, down 2.08% amid bearish technical signals and ongoing financial challenges. The company reported a net loss of $405 million in 2025 with negative profit margins, though revenue showed some recovery to $1.18 billion. Recent news highlights multiple law firm investigations into investor claims while the company pursues AI data center expansion opportunities.
The outlook remains challenging with significant execution risks and negative profitability, though analyst consensus suggests modest upside potential to the $37.75 price target. Key risks include ongoing legal scrutiny, competitive pressures in solar markets, and the company's ability to achieve its ambitious 2029 revenue target of $2.4 billion.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About DexCom, Inc.
Dexcom designs and commercializes continuous glucose monitoring systems for diabetics. CGM systems serve as an alternative to the traditional blood glucose meter process, and the company is evolving its CGM systems to include the disposable sensor and the durable receiver.
Read more on DXCM →About Solaredge Technologies Inc
SolarEdge Technologies designs, develops, and sells direct current optimized inverter systems for solar photovoltaic installations. The company system consists of power optimizers, inverters, and cloud-based monitoring platform and addresses a broad range of solar market segments, from residential solar installations to commercial and small utility-scale solar installations. The company sells its products directly to solar installers, engineering, procurement, and construction firms and indirectly to solar installers through distributors and electrical equipment wholesalers. Additionally, the company has nonsolar products targeting energy storage and e-mobility.
Read more on SEDG →
